– USA, CA – Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, announced the appointment of Christos Richards to its Board of Directors.
“I am delighted to welcome Christos to our Board. His broad and deep knowledge and understanding of the life sciences industry will be invaluable as we continue the transformation of Codexis,” said Chairman and CEO, Dr. SteveDilly .
About Christos Richards
Christos Richards brings over 30 years of global executive advisory and search experience for the biopharmaceutical and healthcare industry to Codexis. To date, he has completed more than 450 executive-level assignments, including over 200 Board, CEO, and CEO succession projects in the Life Sciences sector. He currently serves as Global Head of Healthcare and Life Sciences at Calibre One, a global executive search firm with offices across California as well as Chicago, New York, and London. Christos Richards serves clients from venture-backed startups to leading global enterprises in devices, diagnostics, agricultural biotechnology, animal health, tools, services, and digital health sectors. He has spent 20 years as a partner with two prominent boutique search firms, including serving as CEO of Levin & Company.
Christos Richards previously served on the Board of Directors for Coherus BioSciences and is also an advisor for the University of California, San Francisco Innovation Ventures Entrepreneurship Center.
Christos Richards said, “As a longstanding partner to the biopharmaceutical industry, I’m well aware of the potential of Codexis’ proprietary technologies and their ability to enable the exponential expansion of RNAi therapeutics and other novel therapeutic modalities. I’m thrilled to partner with the management team and Board of Directors to see the company through this next phase of growth.”
Christos Richards holds a diploma in hospitality management from Schweizerische Wirteschule in Lucerne/Davos, Switzerland.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve real-world challenges associated with small-molecule pharmaceutical manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing, and greater sensitivity in genomic and diagnostic applications.
For more: https://www.codexis.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.